Agios Pharmaceuticals (AGIO) Upgraded by BidaskClub to “Sell”

Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Wednesday.

Several other brokerages also recently weighed in on AGIO. Oppenheimer set a $83.00 price objective on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday. Royal Bank of Canada initiated coverage on shares of Agios Pharmaceuticals in a research report on Thursday, September 14th. They set an “outperform” rating and a $78.00 price objective for the company. JPMorgan Chase & Co. restated a “buy” rating and set a $76.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, September 18th. SunTrust Banks restated a “buy” rating and set a $80.00 price objective on shares of Agios Pharmaceuticals in a research report on Wednesday, October 4th. Finally, Cann restated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, December 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $75.70.

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) opened at $59.82 on Wednesday. The firm has a market cap of $2,833.60, a P/E ratio of -9.54 and a beta of 1.83. Agios Pharmaceuticals has a 12-month low of $39.24 and a 12-month high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, topping the consensus estimate of ($1.78) by $0.19. The business had revenue of $11.35 million during the quarter, compared to the consensus estimate of $10.85 million. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The company’s revenue was up 26.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.63) EPS. analysts forecast that Agios Pharmaceuticals will post -6.59 earnings per share for the current year.

In other news, Director Lewis Clayton Jr. Cantley sold 3,838 shares of Agios Pharmaceuticals stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $59.37, for a total value of $227,862.06. Following the transaction, the director now directly owns 80,851 shares of the company’s stock, valued at approximately $4,800,123.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock in a transaction on Friday, December 1st. The shares were sold at an average price of $60.79, for a total transaction of $130,455.34. Following the completion of the transaction, the insider now directly owns 8,410 shares in the company, valued at $511,243.90. The disclosure for this sale can be found here. Insiders sold a total of 127,746 shares of company stock worth $8,733,196 over the last ninety days. Corporate insiders own 5.43% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in AGIO. Aperio Group LLC acquired a new position in Agios Pharmaceuticals in the 2nd quarter valued at $206,000. Great West Life Assurance Co. Can increased its stake in Agios Pharmaceuticals by 84.6% in the 2nd quarter. Great West Life Assurance Co. Can now owns 5,543 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 2,541 shares during the period. Schwab Charles Investment Management Inc. increased its stake in Agios Pharmaceuticals by 16.2% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 96,866 shares of the biopharmaceutical company’s stock valued at $4,984,000 after buying an additional 13,539 shares during the period. Rhumbline Advisers increased its stake in Agios Pharmaceuticals by 25.4% in the 2nd quarter. Rhumbline Advisers now owns 46,282 shares of the biopharmaceutical company’s stock valued at $2,381,000 after buying an additional 9,374 shares during the period. Finally, State of Wisconsin Investment Board increased its stake in Agios Pharmaceuticals by 33.6% in the 2nd quarter. State of Wisconsin Investment Board now owns 8,274 shares of the biopharmaceutical company’s stock valued at $426,000 after buying an additional 2,080 shares during the period. 93.79% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.com-unik.info/2017/12/27/agios-pharmaceuticals-agio-upgraded-by-bidaskclub-to-sell.html.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit